The funding is for the project "Evaluation of chronic toxicity in Risperidone ISM® Quarterly".
1 min
28 Jan, 2022
On the basis of the CHMP’s recommendation, the European Commission will issue its decision on the approval of...
4 min
17 Dec, 2021
ROVI updates its strategy in a meeting with shareholders, investors and analysts
1 min
16 Nov, 2021
ROVI reports operating revenue growth of 53% and doubles its Ebitda
5 min
03 Nov, 2021
ROVI reported the commencement by the Company, effective as of today, 3 November 2021, of a share buyback program
4 min
03 Nov, 2021
Delay in the decision on the granting of marketing authorisation for Risperidone ISM® by the U.S. Food and Drug...
2 min
21 Oct, 2021
Laboratorios Farmacéuticos ROVI, S.A. informs of the joint press release from Moderna and Takeda regarding the...
4 min
01 Sep, 2021
Laboratorios Farmacéuticos ROVI, S.A. has announced that a formal investigation is continuing to determine what...
2 min
29 Aug, 2021
Laboratorios Farmacéuticos ROVI, S.A. has announced that a formal investigation is continuing to determine what...
2 min
29 Aug, 2021